The ongoing COVID-19 pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused enormous global health and socioeconomic damage and requires urgent development of an effective COVID-19 vaccine ([@R1]). While multiple vaccine candidates have entered clinical trials ([@R2]), the molecular features that contribute to an effective antibody response are not clear. Shared antibody responses to specific microbial pathogens have been found where the same genetic elements and modes of recognition are observed in multiple individuals against a given antigen. Such responses to microbial pathogens have been observed against influenza ([@R3]), dengue ([@R4]), malaria ([@R5]), and HIV ([@R6]). Characterization of their molecular interactions with cognate antigen can provide insight into how the immune repertoire is able to quickly respond to novel microbial pathogens, and facilitate rational vaccine design against these pathogens ([@R7], [@R8]).

The spike (S) protein is the major surface antigen of SARS-CoV-2. The S protein uses its receptor-binding domain (RBD) to engage the host receptor ACE2 for viral entry ([@R9]--[@R12]). RBD-targeting antibodies could then neutralize SARS-CoV-2 by blocking ACE2 binding. A number of antibodies that target the RBD of SARS-CoV-2 have now been discovered ([@R13]--[@R28]). We compiled a list of 294 SARS-CoV-2 RBD-targeting antibodies where information on IGHV gene usage is available ([@R17]--[@R28]) (table S1), and found that IGHV3-53 is the most frequently used IGHV gene among these antibodies ([Fig. 1A](#F1){ref-type="fig"}), with 10% encoded by IGHV3-53, compared to 0.5% to 2.6% (mean of 1.8%) in the repertoire of naïve healthy individuals ([@R29], [@R30]). IGHV3-53 antibodies were found in 7 out of 12 studies and in 17 of 32 COVID-19 patient samples ([@R17]--[@R28], [@R31]). These IGHV3-53 antibodies not only had lower somatic mutation rates, but also were more potent compared to other germlines in the cohort investigated here ([@R27]) (fig. S1). The prevalence of IGHV3-53 in the antibody response in SARS-CoV-2 patients has also been recognized in other antibody studies ([@R20], [@R22], [@R27]).

![Structures of two IGHV3-53 antibodies.\
(**A**) The distribution of IGHV gene usage is shown for a total of 294 RBD-targeting antibodies ([@R17]--[@R28]). (**B** and **C**) Crystal structures of (B) CC12.1 in complex with SARS-CoV-2 RBD, (C) CC12.3 with SARS-CoV-2 RBD, and (**D**) human ACE2 with SARS-CoV-2 RBD (PDB 6M0J) ([@R12]).](abd2321-F1){#F1}

To understand the molecular features that endow IGHV3-53 with favorable properties for RBD recognition, we determined crystal structures of two IGHV3-53 neutralizing antibodies, namely CC12.1 and CC12.3, in complex with the SARS-CoV-2 RBD, and with a cross-reactive Fab CR3022 to SARS-like CoVs ([@R17]). CC12.1 and CC12.3 were previously isolated from a SARS-CoV-2-infected patient and shown to specific for the RBD ([@R27]). CC12.1 and CC12.3 (IC~50~ \~20 ng/ml) were among the top four highly potent neutralizing antibodies in the panel of antibodies assayed against live replicating SARS-CoV-2 virus and pseudovirus ([@R27]). Although CC12.1 and CC12.3 are both encoded by IGHV3-53, CC12.1 utilizes IGHJ6, IGKV1-9, and IGKJ3, whereas CC12.3 utilizes IGHJ4, IGKV3-20, and IGKJ1. This variation in IGHJ, IGKV, and IGKJ usage indicates that CC12.1 and CC12.3 belong to different clonotypes, but are encoded by a common IGHV3-53 germline gene (fig. S2). IgBlast analysis ([@R32]) shows that IGHV and IGKV of CC12.1 have acquired only four amino-acid changes (somatic mutations) during affinity maturation from the original germline antibody sequence (fig. S2, A and B). Similarly, CC12.3 is also minimally somatically mutated with three amino-acid changes in IGHV and a single amino-acid deletion in IGKV (fig. S2, A and C). The binding affinities (K~d~) of Fabs CC12.1 and CC12.3 to SARS-CoV-2 RBD are 17 nM and 14 nM, respectively (fig. S3). Moreover, competition experiments suggest that CC12.1 and CC12.3 bind to a similar epitope, which overlaps with the ACE2 binding site, but not the CR3022 epitope (fig. S4).

We determined four complex crystal structures, CC12.1/RBD, CC12.3/RBD, CC12.1/RBD/CR3022, and CC12.3/RBD/CR3022 at resolutions of 3.20 Å, 2.33 Å, 2.70 Å, and 2.90 Å, respectively (table S2). CC12.1 and CC12.3 bind to the ACE2 binding site on SARS-CoV-2 RBD with an identical angle of approach ([Fig. 1, B to D](#F1){ref-type="fig"}, and fig. S5). Interestingly, another IGHV3-53 antibody B38, whose structure was determined recently ([@R23]), binds to the ACE2 binding site on SARS-CoV-2 RBD in a similar manner, but with a K~d~ of 70.1 nM (fig. S6). Similar to the ACE2 binding site ([@R11]), the epitopes of these antibodies can only be accessed when the RBD is in the "up" conformation (fig. S7). Among 17 ACE2 binding residues on RBD, 15 and 16 are within the epitopes of CC12.1 and B38, respectively, and 11 are in the epitope of CC12.3 ([Fig. 2, A to D](#F2){ref-type="fig"}). Many of the epitope residues are not conserved between SARS-CoV-2 and SARS-CoV ([Fig. 2E](#F2){ref-type="fig"}), explaining their lack of cross-reactivity ([@R27]). The buried surface area (BSA) from the heavy-chain interaction is quite similar in CC12.1 (723 Å^2^), CC12.3 (698 Å^2^), and B38 (713 Å^2^). In contrast, the light-chain interaction is much smaller for CC12.3 (176 Å^2^) compared to CC12.1 (566 Å^2^) and B38 (495 Å^2^), consistent with different light-chain gene usage. While both CC12.1 and B38 use IGKV1-9, CC12.3 uses IGKV3-20, which suggests that IGHV3-53 can pair with different light chains to target the ACE2 binding site of the SARS-CoV-2 RBD. CC12.1 (56% BSA from the heavy chain) binds the RBD with similar affinity to CC12.3 (80% BSA from the heavy chain), but with slightly slower dissociation rate (fig. S3), which might be influenced by the different light chain and its greater contribution in CC12.1. Nevertheless, the light-chain identity seems not to be as critical as the heavy chain. In fact, among the RBD-targeting IGHV3-53 antibodies, nine different light chains are observed, although IGKV1-9 and IGKV3-20 are the most frequently found to date (fig. S8).

![Epitopes of IGHV35-3 antibodies.\
(**A** to **C**) Epitopes of (A) CC12.1, (B) CC12.3, and (C) B38 (PDB 7BZ5) ([@R23]). Epitope residues contacting the heavy chain are in orange and the light chain are in yellow. On the left panels, CDR loops are labeled. On the right panels, epitope residues are labeled. For clarity, only representative epitope residues are labeled. Epitope residues that are also involved in ACE2 binding are in red. (**D**) ACE2-binding residues are shown in blue. On the left panel, ACE2 is shown in green within a semi-transparent surface representation. On the right panel, ACE2-binding residues are labeled. A total of 17 residues are used for ACE2 binding ([@R12]), but only 15 are labeled here since the other two are at the back of the structure in this view and do not interact with the antibodies here. (**E**) Epitope residues for CC12.1, CC12.3, and B38 were identified by PISA ([@R41]) and annotated on the SARS-CoV-2 RBD sequence, which is aligned to the SARS-CoV RBD sequence with non-conserved residues highlighted. The 17 ACE2-binding residues were as described previously ([@R12]).](abd2321-F2){#F2}

To understand why IGHV3-53 is elicited as a shared antibody response, the molecular interactions between the RBD and the heavy chains of CC12.1, CC12.3, and B38 were analyzed. The complementarity-determining regions (CDR) H1 and H2 of these antibodies interact extensively with the RBD mainly through specific hydrogen bonds ([Fig. 3, A and B](#F3){ref-type="fig"}). Interestingly, all residues on CDR H1 and H2 that hydrogen bond with the RBD are encoded by the germline IGHV3-53 (fig. S2 and table S3). These interactions are almost identical among CC12.1, CC12.3, and B38 with the only difference at V~H~ residue 58. A somatic mutation V~H~ Y58F in CC12.1 and CC12.3, but not in B38 ([Fig. 3, A to C](#F3){ref-type="fig"}, boxed residues, and fig. S9), results in similar van der Waals' interactions with only a loss of a single hydrogen bond from the hydroxyl of the germline Tyr in B38 to the RBD ([Fig. 3C](#F3){ref-type="fig"}). Of note, none of these antibody interactions mimic ACE2 binding ([Fig. 3D](#F3){ref-type="fig"}).

![Interactions between the RBD and heavy chain CDR loops.\
(**A** to **C**) Highly similar interaction modes between SARS-CoV-2 RBD and the antibody CDR H1 and H2 loops, but not the H3 loop, are observed for (A) CC12.1, (B) CC12.3, and (C) B38 (PDB 7BZ5) ([@R23]). The RBD is in white and antibody residues in cyan, pink, and dark gray, respectively. Oxygen atoms are in red, and nitrogen atoms in blue. Hydrogen bonds are represented by dashed lines. (**D**) The interaction between ACE2 (green) and residues of the RBD (PDB 6M0J) ([@R12]) that are shown in (A) to (C).](abd2321-F3){#F3}

Our structural analysis reveals two key motifs in the IGHV3-53 germline sequence that are important for RBD binding, namely an NY motif at V~H~ residues 32 and 33 in the CDR H1, and an SGGS motif at V~H~ residues 53 to 56 in the CDR H2 ([Fig. 3](#F3){ref-type="fig"} and fig. S10). The side chain of V~H~ N32 in the NY motif hydrogen bonds with the backbone carbonyl of A475 on the RBD, and this interaction is stabilized by an extensive network of hydrogen bonds with other antibody residues as well as a bound water molecule ([Fig. 4A](#F4){ref-type="fig"}). V~H~ N32 also hydrogen bonds with V~H~ R94, which in turn hydrogen bonds with N487 and Y489 on the RBD ([Fig. 4A](#F4){ref-type="fig"}). These polar contacts not only enhance RBD-Fab interaction, but also stabilize the CDR conformations with the surrounding residues (framework). V~H~ Y33 in the NY motif inserts into a hydrophobic cage formed by RBD residues Y421, F456, L455 and the aliphatic component of K417 ([Fig. 4B](#F4){ref-type="fig"}). A hydrogen bond between V~H~ Y33 and the carbonyl oxygen of L455 on the RBD further strengthens the interaction. The second key motif SGGS in CDR H2 forms an extensive hydrogen bond network with the RBD ([Fig. 4C](#F4){ref-type="fig"}), including four hydrogen bonds that involve the hydroxyl side chains of V~H~ S53 and V~H~ S56, and four water-mediated hydrogen bonds to the backbone carbonyl of V~H~ G54, the backbone amide of V~H~ S56, and the side chain of V~H~ S56. Along with V~H~ Y52, the SGGS motif takes part in a type I beta turn, with a positive Φ-angle for V~H~ G55 at the end of the turn. In addition, the Cα of V~H~ G54 is only 4 Å away from the RBD, indicating that side chains of other amino acids would clash with the RBD if they were present at this position.

![Two IGHV3-53 germline-encoded motifs with a short CDR H3.\
(**A**) The extensive hydrogen bond network that involves V~H~ N32 of the NY motif in CDR H1 is illustrated. (**B**) The hydrophobic cage interaction between the RBD and V~H~ Y33 of the NY motif in CDR H1 is shown. (**C**) The hydrogen bond network that involves the SGGS motif in CDR H2 is highlighted. CC12.3 is shown here because its structure is at higher resolution than CC12.1. (**D**) CDR H3 length is constrained to fit in a relatively small pocket on the RBD surface. The heavy and light chains of CC12.1 (cyan), and the RBD (white) are shown in surface representation, with CDR H3 (red) highlighted in cartoon representation in the left panel. CC12.3 (pink) is shown in the right panel in the same representation.](abd2321-F4){#F4}

The NY and SGGS motifs, important for RBD binding, are both encoded in the IGHV3-53 germline gene. Besides IGHV3-53, only the closely related IGHV3-66 contains an NY motif in CDR H1 and an SGGS motif in CDR H2 ([@R33]). IGHV3-66 is also commonly observed ([@R19]--[@R22], [@R24], [@R26]) in antibodies in SARS-CoV-2 patients ([Fig. 1A](#F1){ref-type="fig"}), and is also well represented in the repertoire of healthy individuals (0.3% to 1.7% of total antibodies) ([@R29]). Overall, our structural analysis has identified two germline-encoded binding motifs that enable IGHV3-53 to target the SARS-CoV-2 RBD with mutations apparently not required from affinity maturation.

While the binding mode of CDR H1 and H2 to RBD is highly similar among CC12.1, CC12.3, and B38, CDR H3 interaction with the RBD varies ([Fig. 3, A to C](#F3){ref-type="fig"}) due to differences in the CDR H3 sequences and conformations (fig. S1 and [Fig. 4D](#F4){ref-type="fig"}). For example, while CDR H3 of CC12.1 interacts with RBD Y453 through a hydrogen bond, CDR H3 of CC12.3 and B38 do not form such a hydrogen bond ([Fig. 3, A to C](#F3){ref-type="fig"}). Similarly, due to the difference in light-chain gene usage, light-chain interactions with the RBD can vary substantially in IGHV3-53 antibodies (fig. S11). Overall, our structural analysis demonstrates that IGHV3-53 provides a versatile framework to target the ACE2 binding site in SARS-CoV-2 RBD.

An interesting feature of CC12.1 and CC12.3 is their relatively short CDR H3. While the CDR H3 sequences of CC12.1 and CC12.3 differ, both are nine amino acids in length (Kabat numbering) ([@R34]). Antibody B38 has an even shorter CDR H3 of seven residues ([@R23]). The average CDR H3 length for human antibodies is around 13 ([@R35]), although very long CDR H3s (up to 30 residues) are found in many broadly neutralizing antibodies to HIV-1 ([@R36]). Longer CDR H3′s cannot be accommodated in these IGHV3-53 antibodies since their epitopes are relatively flat with only a small large pocket to insert their CDR H3 loop ([Fig. 4D](#F4){ref-type="fig"}). A similar conclusion was reached in another recent study, which also reported that SARS-CoV-2 RBD-targeting antibodies encoded by IGHV3-53 or IGHV3-66 tend to have a short CDR H3 ([@R28], [@R37]). Consistently, among the RBD-targeting antibodies currently reported ([@R17]--[@R28]), IGHV3-53 antibodies have a significantly shorter CDR H3 compared to those encoded by other IGHV genes (p-value = 6e-8, Mann-Whitney U test) (fig. S12), and shorter than IGHV3-53-encoded antibodies in the naïve human antibody repertoire ([@R30]). Thus, a short CDR H3 length is one of the molecular features of the IGHV3-53-encoded antibody response to SARS-CoV-2 RBD, reminiscent of a below average 5-residue CDR L3 in IGHV1-2 antibodies to the receptor binding site in HIV-1 Env gp120 ([@R38]). Nevertheless, a small subset of these IGHV3-53 antibodies have longer CDR H3s that warrant further investigation of their binding mode (fig. S12).

Besides IGHV3-53, several other IGHV genes such as IGHV1-2, IGHV3-9, and IGHV3-30 are also more frequently observed than other germlines in SARS-CoV-2 RBD-targeting antibodies ([Fig. 1A](#F1){ref-type="fig"}). The molecular mechanisms of these IGHV responses to SARS-CoV-2 need characterization, as well as whether other germline gene segments, including IGHD and the light chain contribute in recurring motifs to the SARS-CoV-2 antibody response. The characterization of these IGHV3-53 antibodies to SARS-CoV-2 is a promising starting point for rational vaccine design ([@R39]), given that limited to no affinity maturation is required to achieve a highly potent neutralizing antibody response to the RBD. As IGHV3-53 is found at a reasonable frequency in healthy individuals ([@R29], [@R30]), this particular antibody response could be commonly elicited during vaccination ([@R40]).
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